Skip to content

Study · Systematic review · n = 13,947 · 2025

4 results

Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.

Garbaccio NC, Smith JE, Posso A, Schonebaum DI, Foster L, Cordero JJ, Foppiani J, Alvarez AH, Choudry U, Lin SJ

Aesthetic plastic surgery20 Aug 2025Cited by 3 (Europe PMC)

PMID40835770 (opens in a new tab)DOI10.1007/s00266-025-05112-3 (opens in a new tab)PepBankPUB-40835770
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of 12 studies of semaglutide, weight loss plateaued at 53.0 weeks.

    In plain wordsIn a review of 12 studies, weight loss on semaglutide levelled off after about 53 weeks.

    Peptide
    Semaglutide
    Outcome
    Not applicableTime to weight loss plateau
    Study

    n = 13,947

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Time to weight loss plateau
    53 weeks
    semaglutide

    Source sentences

    Summary
    WLP occurred at 53.0±8.2 weeks at 16% (±3.1%) WL, deviating from greatest on-treatment WL by 2% (±0.7%) and end-of-treatment WL by 1% (±1.2%).
    2 context sentences
    Summary · context
    Of 555 studies, 12 met inclusion criteria (n=13,947 patients)
    Summary · context
    Randomized controlled trials (RCTs) and prospective observational studies measuring weight change over time with semaglutide use were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of 12 studies of semaglutide, weight loss at the plateau was 16%.

    In plain wordsIn a review of 12 studies, people on semaglutide had lost about 16% of their weight when weight loss levelled off.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss at plateau
    Study

    n = 13,947

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss at plateau
    16%
    semaglutide

    Source sentences

    Summary
    at 16% (±3.1%) WL, deviating from greatest on-treatment WL by 2% (±0.7%) and end-of-treatment WL by 1% (±1.2%).
    2 context sentences
    Summary · context
    Of 555 studies, 12 met inclusion criteria (n=13,947 patients)
    Summary · context
    Randomized controlled trials (RCTs) and prospective observational studies measuring weight change over time with semaglutide use were included.
  3. 03HumanSystematic reviewEfficacy outcome

    The plateau deviated from the greatest on-treatment weight loss by 2% and from the end-of-treatment weight loss by 1%.

    In plain wordsIn a review of 12 studies, weight at the plateau was within 1% to 2% of the lowest weight reached on semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePlateau weight loss compared with greatest and end-of-treatment weight loss
    Study

    n = 13,947

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Deviation from greatest on-treatment weight loss
    2%
    plateau
    Deviation from end-of-treatment weight loss
    1%
    plateau

    Source sentences

    Summary
    deviating from greatest on-treatment WL by 2% (±0.7%) and end-of-treatment WL by 1% (±1.2%).
    2 context sentences
    Summary · context
    Of 555 studies, 12 met inclusion criteria (n=13,947 patients)
    Summary · context
    Randomized controlled trials (RCTs) and prospective observational studies measuring weight change over time with semaglutide use were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In two studies after semaglutide discontinuation, participants regained 62.7% and 74.3% of the greatest on-treatment weight loss at the end of observation.

    In plain wordsIn two studies, people who stopped semaglutide regained 62.7% and 74.3% of the weight they had lost at the end of follow-up.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight regain after drug discontinuation
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight regained (12 weeks post-discontinuation)
    62.7 % of greatest weight loss
    after stopping semaglutide
    Weight regained (24 weeks post-discontinuation)
    74.3 % of greatest weight loss
    after stopping semaglutide

    Source sentences

    Summary
    By the end of the observation period, participants regained 62.7 and 74.3% of greatest on-treatment WL, respectively
    2 context sentences
    Summary · context
    Two studies assessed WR following drug discontinuation. WR occurred at 12 weeks and 24 weeks post-discontinuation.
    Summary · context
    Randomized controlled trials (RCTs) and prospective observational studies measuring weight change over time with semaglutide use were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.